A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes
← catalyst calendarNCT07668388 · readout in 411 d
Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
300estimated
Sites
70
Countries
Australia, Germany, Hungary +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-06-22 | actual | When the study began enrolling |
| Primary completion | 2027-10-04 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-11-15 | estimated | The whole study's end, after follow-up |
| First posted | 2026-06-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Diabetes Mellitus, Type 2
Interventions
- Drug: UBT251
- Drug: UBT251 Placebo
- Drug: Semaglutide
- Drug: Semaglutide Placebo
Primary outcome
what the primary-completion date above is the date OFUBT251: Change in glycated haemoglobin (HbA1c)
measured From baseline (week 0) to 12 weeks on a given maintenance dose (week 16, 28 and 40)
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed